Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975829 · ClinicalTrials.gov registry record · Phase 4
Pediatric Long-Term Follow-up and Rollover Study
A Phase 4 study of Glioblastoma and Anaplastic Astrocytoma, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
- 20
- Study locations
NCT03975829: Active Phase 4 study of Glioblastoma and Anaplastic Astrocytoma, sponsored by Novartis Pharmaceuticals.
NCT03975829 is a Phase 4 study of Glioblastoma and Anaplastic Astrocytoma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 163 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03975829, a Phase 4 study of Glioblastoma and Anaplastic Astrocytoma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
- 20
- Study locations
Study Summary
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Primary Outcome
To assess the long-term safety of treatment with dabrafenib, trametinib or the combination.
Conditions Studied
Interventions
- DRUG dabrafenib
- DRUG trametinib
Study Locations (20)
São Paulo
- Novartis Investigative Site - Barretos
- Novartis Investigative Site - São Paulo
- Novartis Investigative Site - São Paulo
New York
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Cancer Ctr - New York
Arizona
- Phoenix Children s Hospital - Phoenix
District of Columbia
- Childrens National Hospital - Washington D.C.
Florida
- Nicklaus Childrens Hospital - Miami
Indiana
- Indiana Uni School of Medicine - Indianapolis
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2026-11-06 |
| Phase | Phase 4 |
What the registry record for NCT03975829 still lists
NCT03975829 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (51% higher).
The record links to 10 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which dabrafenib is the first listed.
NCT03975829 names 20 study sites across 17 states, led by São Paulo, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT03975829 about?
NCT03975829 is a clinical study titled "Pediatric Long-Term Follow-up and Rollover Study". A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
What is the current status of trial NCT03975829?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2019-11-04. Estimated completion is 2026-11-06.
What conditions does trial NCT03975829 study?
This clinical trial studies the following conditions: Glioblastoma, Anaplastic Astrocytoma, Astrocytoma, Anaplastic Oligodendroglioma, Pilocytic Astrocytoma.
What interventions are being tested in trial NCT03975829?
The interventions under investigation include: dabrafenib (DRUG), trametinib (DRUG).
Who is sponsoring clinical trial NCT03975829?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03975829 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03975829's enrollment target sits among peer trials
163 30th of 199 higher than 170 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GammaTile and Stupp in Newly Diagnosed GBM
ACTIVE NOT RECRUITING · Phase 4
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI